Mycobacterium avium is a common source of disseminated bacterial infection in patients with AIDS (4, 5) . T cells play a central role in the development of protective immunity to M. avium (1, 6-8, 10, 12) , but few antigens of M. avium have been cloned and characterized (11, 16, 19, 22) , and nothing is known about which antigens of M. avium stimulate protective immune responses. We have recently identified a family of mycobacterial proteins termed fibronectin attachment proteins (FAPs) and have characterized their role in the uptake of mycobacteria into cells (14, 19, 20) . We also have cloned the M. avium cognate of FAP, FAP-A, and have identified two sites within the molecule which bind to fibronectin. These two sites are highly conserved between FAP-A, FAP-L, and the recently cloned apa-encoded protein of Mycobacterium tuberculosis (FAP-TB) (9, 19) . Intriguingly, the amino acid sequences of the cloned FAPs revealed that they are closely related to a family of proteins which are rich in proline and alanine residues and which have been demonstrated to play a role in immune responses to several mycobacterial species (3, 9, 15, 17, 21) . Most intriguing, immune responses in guinea pigs to the 45/47-kDa complex of Mycobacterium bovis BCG (FAP-BCG) were observed by Marchal and colleagues only when the guinea pigs were inoculated with live, but not heat-killed, M. bovis BCG, an immunization protocol which has been shown to be most effective at eliciting protective immunity (15) . In addition, our studies of the function of FAP suggested that an immune response directed against this protein might protect against M. avium infection. We therefore set out to study the role that FAP-A plays in murine immune responses to M. avium.
To generate large quantities of FAP-A, we expressed it as a recombinant protein in Escherichia coli by use of the pTrcHis vector and purified it to homogeneity with a nickel column followed by reverse-phase high-performance liquid chromatography. We used two FAP-A fusion proteins, FAP-A(1-381), comprising the entire amino acid sequence of the protein, and FAP-A(136-381). To determine first whether rFAP-A is immunogenic in mice, BALB/c (H-2 d ) mice were immunized with rFAP-A(1-381) emulsified in incomplete Freund's adjuvant (IFA). Lymph node (LN) cells from mice primed with rFAP-A mounted a vigorous proliferative response to the immunogen (Fig. 1) . In contrast, LN cells from naive mice failed to respond. We also detected a strong T-cell proliferative response to FAP-A in B10.BR mice (data not shown).
To identify the T-cell epitopes of the FAP-A molecule recognized by BALB/c (H-2 d ) and B10.BR (H-2 k ) mice, we employed a panel of 38 synthetic peptides varying from 18 to 30 amino acids in length, which spanned the entire sequence of FAP-A (13, 18) . BALB/c mice were immunized with FAP-A(1-381) emulsified in IFA. One week later, LN cells were stimulated with each peptide of the panel as described elsewhere (23) . Three peptides spanning the region of amino acids 280 to 314 specifically stimulated the FAP-A-primed LN cells ( (Fig. 2B ). FAP-A-primed B10.BR mice mounted a specific, vigorous proliferative response to a peptide comprising amino acids 243 to 268. Thus, as with BALB/c mice, the predominant T-cell response of B10.BR mice to FAP-A is directed against a single but distinct region of the molecule. Interestingly, these two regions, like the fibronectin-binding domains, are located in the most highly conserved region of the FAP molecule, which contains few alanine and proline residues (19) . (Fig. 3A) . These cells also gave a strong response to a peptide comprising the cognate region of FAP-TB. There was no significant response to a peptide with amino acid sequences derived from FAP-L, however. A similar experiment was performed with BALB/c mice (Fig. 3B) . LN cells from FAP-A-primed mice responded vigorously to the immunodominant FAP-A(288-302) peptide, whereas there was no response to peptide with amino acid sequences derived from FAP-TB or FAP-L. Thus, for BALB/c mice, T cells primed to FAP-A are not cross-reactive to FAPs of other mycobacterial species, whereas for B10.BR mice, T cells primed to FAP-A cross-react with FAP-TB.
To determine whether an immune response to FAP-A occurred during infection, we tested whether LN cells from mice infected with live M. avium (2) (Fig. 4) . The T cells also significantly responded to the FAP-A(288-302) peptide (P Ͻ 0.05; Student's t test). Similarly, LN cells from infected B10.BR mice responded to the FAP-A(249-262) peptide (data not shown). These findings confirmed that the FAP-A(288-302) epitope is presented in vivo but that other FAP-A epitopes also are recognized during infection. Overall, these data indicate that T cells are stimulated by a FAP-A molecule during an infection with live M. avium and suggest that FAP-A could in part contribute to the development of protective T-cell immunity to M. avium. The sequence of FAP-A reveals that 40% of the amino acids are either proline or alanine. The amino-and carboxy-terminal portions of the protein are particularly rich in these residues. The prolines would hinder efficient antigen processing and presentation because of their inaccessibility to many proteolytic enzymes. The immunodominant epitopes defined for the two strains of mice are located in a region of FAP-A which is relatively poor in proline and alanine residues (19) .
Taken together with earlier studies of the role of FAPs in immune responses to mycobacteria, our data suggest that the processing and presentation of FAP-A by M. avium-infected macrophages to T cells may contribute to the development of protective immunity to this pathogen. However, given that FAP is likely to be involved in the uptake of mycobacteria into epithelial cells, it will be of interest to direct anti-FAP immune responses to the intestinal mucosa. Nevertheless, the information obtained from analyzing immune responses to individual proteins such as FAP-A could serve as the basis for designing subunit vaccines which employ a collection of antigens.
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